RIPK3 and central nervous system cancer: Kaplan–Meier analyses of 703 glioma patients in TCGA revealed that while expression of RIPK1, RIPK3, and MLKL did not correlate with OS in grade II tumors, high expression of each was associated with significantly reduced OS in grade III gliomas (HR = 2.03, p = 0.002; HR = 2.09, p = 0.002; HR = 2.10, p = 0.001, respectively) (Fig. S4A–C).